ASTELLAS TO FORM STRATEGIC PARTNERSHIP WITH CLEARPATH TO BUILD VACCINE PORTFOLIO
Tokyo, Japan; Rockville, MD; and Epalinges, Switzerland – January 6, 2014
Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas’ goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013. Astellas will fund RSVC’s development of a virosome vaccine technology, licensed from Mymetics Corporation (Mymetics ‐ OTC BB: MYMX), for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof‐of‐concept study. Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Astellas ClearPath Mymetics Release 01-06-14_FINAL | Download |